IL18 and neoplasm: In addition, IL18R1 binds the anti-inflammatory and immune-suppressive IL-37 [92]; despite dampening host's immune responses, this interleukin shows interesting anti-tumour properties [93] and, in oral squamous cell carcinoma, serum IL-18/IL-37 ratio seems to regulate CD19+ B cells and CD3+ CD8+ T cells, thus representing a biomarker for predicting overall survival and disease-free survival [94].